La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Grifols Performance dei guadagni passati

Il passato criteri di controllo 2/6

Gli utili di Grifols sono diminuiti a un tasso medio annuo di -42.1%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 11.8%. I ricavi sono cresciuti crescere a un tasso medio annuo di 6.7%. Il ritorno sul capitale proprio di Grifols è 2.8% e ha margini netti di 2.4%.

Informazioni chiave

-42.1%

Tasso di crescita degli utili

-34.1%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	-7.2%
Tasso di crescita dei ricavi	6.7%
Rendimento del capitale proprio	2.8%
Margine netto	2.4%
Prossimo aggiornamento sui guadagni	07 Nov 2024

Aggiornamenti sulle prestazioni recenti

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Ripartizione dei ricavi e delle spese

Come Grifols guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BME:GRF Ricavi, spese e utili (EUR Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	6,811	166	1,391	387
31 Mar 24	6,656	189	1,384	385
31 Dec 23	6,592	59	1,367	395
30 Sep 23	6,535	23	1,343	388
30 Jun 23	6,479	-5	1,217	388
31 Mar 23	6,358	47	1,345	390
31 Dec 22	6,064	208	1,190	361
30 Sep 22	5,549	149	1,138	353
30 Jun 22	5,207	66	1,122	358
31 Mar 22	5,016	112	1,064	359
31 Dec 21	4,933	189	1,062	355
30 Sep 21	5,044	361	1,046	337
30 Jun 21	5,199	667	1,008	311
31 Mar 21	5,231	562	992	298
31 Dec 20	5,340	619	986	294
30 Sep 20	5,392	687	971	288
30 Jun 20	5,353	557	976	286
31 Mar 20	5,235	697	959	281
31 Dec 19	5,099	625	943	276
30 Sep 19	4,961	552	923	271
30 Jun 19	4,790	565	878	261
31 Mar 19	4,620	568	859	249
31 Dec 18	4,487	597	815	241
30 Sep 18	4,332	699	777	212
30 Jun 18	4,246	704	804	215
31 Mar 18	4,279	672	800	219
31 Dec 17	4,318	663	860	225
30 Sep 17	4,348	571	857	230
30 Jun 17	4,291	559	827	222
31 Mar 17	4,153	554	810	209
31 Dec 16	4,050	545	775	198
30 Sep 16	4,014	537	771	216
30 Jun 16	3,986	535	776	218
31 Mar 16	3,985	529	768	221
31 Dec 15	3,935	532	736	224
30 Sep 15	3,789	533	696	211
30 Jun 15	3,645	507	686	199
31 Mar 15	3,466	478	666	194
31 Dec 14	3,355	470	661	181
30 Sep 14	3,133	417	647	161
30 Jun 14	2,972	388	614	150
31 Mar 14	2,856	376	584	132
31 Dec 13	2,742	346	558	123
30 Sep 13	2,708	326	558	124

Guadagni di qualità: GRF ha guadagni di alta qualità.

Margine di profitto in crescita: GRF è diventata redditizia in passato.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di GRF sono diminuiti del 42.1% all'anno negli ultimi 5 anni.

Accelerare la crescita: GRF è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.

Guadagni vs Settore: GRF è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -0.08% ).

Grifols Performance dei guadagni passati

Il passato criteri di controllo 2/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: Revenues in line with analyst expectations

Recent updates

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment deteriorates as stock falls 16%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Consensus EPS estimates fall by 12%

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate